Sumitomo Pharma Balance Sheet Health
Financial Health criteria checks 2/6
Sumitomo Pharma has a total shareholder equity of ¥114.2B and total debt of ¥389.4B, which brings its debt-to-equity ratio to 340.8%. Its total assets and total liabilities are ¥799.8B and ¥685.5B respectively.
Key information
340.8%
Debt to equity ratio
JP¥389.38b
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥99.08b |
| Equity | JP¥114.24b |
| Total liabilities | JP¥685.52b |
| Total assets | JP¥799.77b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: DNPU.F's short term assets (¥311.9B) do not cover its short term liabilities (¥484.2B).
Long Term Liabilities: DNPU.F's short term assets (¥311.9B) exceed its long term liabilities (¥201.3B).
Debt to Equity History and Analysis
Debt Level: DNPU.F's net debt to equity ratio (254.1%) is considered high.
Reducing Debt: DNPU.F's debt to equity ratio has increased from 5.8% to 340.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNPU.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if DNPU.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.